H.C Wainwright lowers the target on Arcellx Inc. (ACLX:NSD) to $40

Arcellx Inc Stock Forecast:

The average analyst target price for Arcellx Inc over the next 12 months is USD 36.83, and the company has a strong buy rating among analysts. However, Stock Target Advisor‘s own analysis of the stock is neutral, based on 3 positive signals and 3 negative signals. Arcellx Inc’s current stock price is USD 30.25, which has increased by +0.83% over the past week, +8.00% over the past month, and +115.76% over the last year.

Analysts Coverage Change:

  • H.C. Wainwright maintains a “Buy” rating for Arcellx Inc and lowers the price target to $40 from $42 on the company’s stock.
  • SVB Leerink maintains an “Outperform” rating and raises the price target to $39 from $35.

ACLX Ratings by Stock Target Advisor

Positive Fundamentals:

  • High market capitalization: company is one of the largest in its sector and among the top quartile
  • Superior risk adjusted returns: stock has performed well compared to sector peers for a hold period of at least 12 months and is in the top quartile
  • Low volatility: stock’s annual returns have been stable and consistent compared to sector peers for a hold period of at least 12 months and is in the top quartile
  • Stability is good for limiting risk, but it can also limit returns.

Negative Fundamentals:

  • Stock is overpriced compared to book value.
  • Trading high compared to peers’ median on a price to book value basis.
  • Company had negative total cash flow in the most recent four quarters.
  • Company had negative total free cash flow in the most recent four quarters.

FA Score (Fundamental Analysis):

The fundamental analysis of Arcellx Inc. is “Neutral” with a FA score of 5 out 0f 10, where 0 is very bearish and 10 is very bullish.

About Arcellx Inc.:

Arcellx is a biotechnology company focused on developing immunotherapies for cancer and other incurable diseases. Its lead product candidate, CART-ddBCMA, is currently in phase 1 clinical trial for treating relapsed or refractory multiple myeloma. Additionally, the company is developing immunotherapeutic combinations such as ACLX-001, ACLX-002, and ACLX-003 to treat various types of cancer. Arcellx has a strategic alliance with Kite for co-developing and co-commercializing CART-ddBCMA. The company was formerly known as Encarta Therapeutics and is headquartered in Gaithersburg, Maryland.

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Very Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *